Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is difficult to treat, and even in a situation where an operation can be
performed to remove the cancer, the disease can unfortunately come back soon afterwards. When
pancreatic cancer is more advanced, the outcomes are even less positive. Recently, a large
international study showed that combining a chemotherapy drug that is standard for treating
pancreatic cancer, called gemcitabine with a new chemotherapy drug called Abraxane was more
effective than gemcitabine alone for patients with advanced pancreatic cancer.
The purpose of this study is to determine whether this combination of gemcitabine and
Abraxane can shrink a pancreatic cancer that is not thought to be operable enough to enable
it to be removed by surgery. It is hoped that in this way, the treatment may improve the
outcome. In addition, in this study we would like to analyse the appearances of the tumour
using imaging, and collect blood and tumour samples to try to confirm laboratory research
that has been carried out with this treatment.
Phase:
Phase 2
Details
Lead Sponsor:
CCTU- Cancer Theme
Collaborators:
Cambridge University Hospitals NHS Foundation Trust Cancer Research UK Celgene